Introduction
Mammalian atrial myocytes synthesize and release the 28 amino acid residue peptide, atrial natriuretic factor (ANF). Raised venous pressure, leading to atrial distension, is one of the factors which releases ANF into the systemic circulation (Anderson et al., 1986; Gerbes et al., 1986) . In addition to promoting natriuresis and diuresis the peptide causes hypotension, due principally to a fall in peripheral vascular resistance (see reviews by Genest & Cantin, 1988; Gerbes et al., 1987) . However, the regional distribution of its vasodilator activity has not been fully examined.
Elevated central venous pressure also leads to raised hepatic venous pressure with profound consequences for hepatic haemodynamics and trans-sinusoidal fluid exchange (Laine et al., 1979) . Enlargement of the liver with movement of fluid across the hepatic capsule into the peritoneal space may be a normal, although temporary compensating mechanism to expand the extravascular fluid space. However, chronic elevation of hepatic venous pressure leads to the persistent presence of excess peritoneal (ascitic) fluid. A significant fraction of the raised hepatic venous pressure may be transmitted through the liver to elevate portal pressure (Bennett & Rothe, 1981) causing enlargement of the spleen (Withrington et al., 1980) , together with venous congestion and oedema of the gastrointestinal tract.
The aim of the present experiments was to characterize the actions of ANF on the primary intra-hepatic resistance sites in the hepatic arterial and portal vascular beds which control total liver blood inflow and, in addition, to assess its molar potency relative to other vasoactive agents. In this way some conclusions could be drawn about the role of ANF in the regulation of total liver blood flow and its distribution between the two inflow circuits both under normal conditions and in those clinical situations where the systemic circulating levels of ANF deviate significantly from normal. A preliminary account of some of these results has been published (Dhume et al., 1988) .
Methods
The experiments were performed on 10 dogs (mean weight 21.9 + 2.0 kg, range 10.0-29.0 kg) anaesthetized with an intravenous mixture of chloralose and urethane (50 and 500mgkg1' respectively) after induction with methohexitone sodium (6 mg kg-1). The trachea was cannulated although respiration was spontaneous throughout the experiment. The right femoral vein was cannulated to administer additional anaesthetic when appropriate. The right femoral artery was cannulated to provide hourly blood samples for analysis of pH, Po2 and Pco2 (Blood Gas Analyser, Instrumental Laboratory, Model 1302); NaHCO3 was administered i.v.
(1.Ommolmin-1) when necessary, to maintain a normal arterial pH. The left carotid artery was cannulated and connected to a strain gauge transducer (Statham P23Gb), to provide a continuous registration of phasic systemic blood pressure from which a continuous recording of heart rate was derived electronically. Body temperature was maintained within normal limits, as indicated by a buccal thermometer, by either table heaters or overhead lamps. The animals were heparinised (500iukg-1) once perfusion had started and half this dose was administered hourly.
The perfusion circuits and surgery required for hepatic arterial and portal perfusion have been described in detail previously (Corder & Withrington, 1988) and in all essential details the same procedure was adopted for the present series. Briefly, the hepatic artery was cannulated after ligation of major side tributaries, and perfused with arterial blood from the cannulated left femoral artery. The Hepatic arterial vascular responses to intra-arterial injections Isoprenaline The non-selective f-adrenoceptor agonist isoprenaline (Iso) was administered in all the hepatic arterial preparations as a bolus injection over a range of doses (0.1-50nmol) to construct, in each experiment, a complete doseresponse curve. The only vascular response observed to i.a. Iso was an increase in hepatic arterial blood flow [HABF] which was graded with dose and of relatively short duration (Figure 1) Intra-arterial dose (-log mol) ranolol (Richardson & Withrington, 1977) and the selective f2-adrenoceptor antagonist, ICI 118,551 (Withrington, 1987) . The threshold dose was usually between 0.1 and 0.5 nmol and the maximum vascular response achieved at either 10 or 20nmol. In the current series of perfusion experiments the mean maximum increase in blood flow to Iso was 72 + 16% of the control flow whilst the mean molar dose of Iso to decrease the hepatic arterial vascular resistance by 50% of the maximum was 0.42 + 0.13 nmol.
Atrial natriuretic factor In the 6 arterial perfusion preparations ANF was administered as a bolus injection (on 54 occasions), in doses from 0.1-50 nmol to construct 8 doseresponse curves, in most cases from the threshold value to maximum effect. The threshold dose of ANF to obtain a hepatic arterial response was usually 0.1-0.5 nmol whilst the maximum response was elicited at either 20 or 50 nmol. The only hepatic arterial vascular response to i.a. ANF was an increase in arterial blood flow, graded with dose, and of the same time course as that observed with i.a. Iso (Figure 1 ). These increases in arterial flow at constant perfusion pressure reflect hepatic arterial vasodilatation. A vasoconstrictor response to intra-arterial ANF was never observed. In any individual experiment (e.g. Figure 2 ) the dose-response curve relating the molar dose of ANF to the increase in hepatic arterial blood flow always lay to the right of that for Iso; i.e. it was less potent hepatic arterial vasodilator. The mean maximum increase in hepatic arterial blood flow to ANF was 61 + 11% of the control value; this is not signifi- Intra-arterial dose (-log mol) Figure 3 Relationship between the intra-arterial molar dose of isoprenaline (0), atrial natriuretic factor (A) and adrenaline (0) and the decrease in hepatic arterial vascular resistance (hepatic arterial vasodilatation) expressed as a percentage of the control resistance prior to the injection. The points represent the means and the vertical bars the s.e. of at least 6 observations. The data for isoprenaline and atrial natriuretic factor were from the current series whilst the adrenaline results come from a previous series of similar preparations (see Richardson & Withrington, 1977 ; Figure 2 ).
cantly different (P > 0.5) from the maximum vasodilator effect to i.a. Iso. However there is a difference in the position of the mean dose-response curve (Figure 3) (Richardson & Withrington, 1977 ) the dose-response curve for adrenaline was constructed and this is included in Figure 3 for comparison (see Discussion).
Hepatic portal responses to intraportal injections of atrial natriureticfactor and noradrenaline ANF was injected as a bolus into the portal circuit on 22 occasions in four perfusion preparations in doses ranging from 1.0-50nmol. The results were unequivocal in that no change in portal inflow pressure was observed on any occasion (Figure 4 ). These observations clearly indicate that, at constant inflow volume, no change in portal inflow resistance was elicited with the range of doses of ANF administered in this series. In 3 of the 4 experiments the higher intraportal bolus doses of ANF were observed to cause systemic hypotension indicating passage of the peptide through the liver into the systemic circulation and peripheral vasodilatation thus confirming the biological activity of the injectate. In the same experiments noradrenaline (NA) was administered (6.0-600nmol) intraportally to elicit graded increases in portal pressure and portal vasoconstriction confirming the reactivity of the preparation. Figure 4 Records of the hepatic portal mean perfusion pressure (HPVP) when the portal circuit was perfused with mesenteric blood at constant flow (146 ml min -). The two panels illustrate the changes in portal pressure, and therefore in portal inflow resistance in response to intraportal bolus injections of noradrenaline (NA, 60 and 120nmol) or atrial natriuretic factor (ANF 1.0, 5.0, 10 and 20 nmol). Liver weight 588 g.
Discussion
The infusion of ANF (0.5 yg min 1) into normal man causes a 20% reduction in apparent liver blood flow (Biollaz et al., 1986) as assessed by iodocyanin green clearance technique. However, such a fall in flow may arise from the reflex adjustments of the hepatic circulation to maintain systemic blood pressure. In addition such information does not provide data on any differential flow changes in the two hepatic inflow circuits. We have been concerned to establish any selective actions of ANF on those parameters of the hepatic circulation which control total liver blood flow and its distribution between the arterial and portal inflow circuits. Histochemical studies have indicated the presence of ANF binding sites along the hepatic arterial and portal vascular territories. Using [1125]-ANF, Bianchi et al. (1985) , demonstrated labelling in the endothelium and smooth muscle of both arterial and portal inflow circuits of the rat. No binding sites were observed along the mesenteric artery.
Close-arterial injection of ANF avoids any of the reflex changes in the peripheral circulation which inevitably follow systemic administration with consequent falls in mean BP. It also mimics the normal route of access of ANF into the liver via the arterial supply. In the current experiments, ANF caused a marked hepatic arterial vasodilatation of short duration with a maximum percentage increase in blood flow not significantly different from that elicted by the non-selective fiadrenoceptor agonist, Iso. However, the molar potency of ANF, as assessed by the molar ED50, was significantly less than Iso.
However, Iso is not a natural endogenous agent so that a more meaningful comparison, to assess any physiological role of ANF, is with the mixed a-and f-adrenoceptor agonist adrenaline (Ad). The hepatic arterial responses to i.a. ADR are complex (Figure 3 ) since they represent the overlapping excitation of both ac-and fi2-adrenoceptors (Richardson & Withrington, 1977) The effect of ANF on portal haemodynamics is more difficult to assess. In the present experiments ANF caused no change in portal inflow resistance when the bed was perfused with mesenteric venous blood at constant flow. In this series no experimental information was obtained about ANF on the other principal determinant of portal haemodynamics, mesenteric flow. Employing chronically implanted pulsed Doppler flow probes in the conscious normotensive rat, Gardiner et al. (1988) observed a fall in mesenteric flow and vasoconstriction following bolus i.v. ANF. Garcia et al. (1984) described the relative insensitivity of isolated mesenteric resistance vessels to the relaxant properties of ANF compared to preparations from other vascular territories. Tentative conclusions from these results might explain the fall in total hepatic flow reported in man by Biollaz et al. (1986) since the change in total flow would depend upon the respective extents of arterial dilatation and the fall in portal inflow from the mesenteric circuit. ANF appears to have a unique spectrum of pharmacological activity since it causes marked hepatic arterial dilatation yet without either mesenteric or hepatic portal vasodilatation. It may therefore change total liver blood flow in favour of the arterial component. This differential activity of ANF may suggest some therapeutic potential.
It is clear, however, that in terms of its absolute molar potency, ANF is amongst the least potent vasodilator substances present in the hepatic inflow circuits. Many other vasoactive substances, particularly peptides of gastrointestinal origin (see review, Withrington & Richardson, 1989) enter the liver in the portal inflow principally during digestion. It is now established that vasoactive substances present in the portal inflow alone may nevertheless have access to hepatic arterial resistance sites by 'transhepatic routes' (Richardson & Withrington, 1978; Lautt et al., 1984) . It remains an important aspect of hepatic circulatory physiology to establish any interactions, on the liver vasculature, between substances of primarily systemic origin (i.e. ANF) with those of GI origin (i.e. substance P). In this way the extent to which hepatic haemodynamics is related to, and integrated with, systemic and GI events, may be evaluated.
The physiological and pathophysiological role of ANF in liver haemodynamics remains to be fully elucidated. In the absence of other changes then hepatic arterial vasodilatation to ANF would increase the extent of fluid formation within the liver by increasing mean capillary pressure, enlarge the liver and promote movement of fluid across the liver capsule into the peritoneal space. In this way ANF may contribute towards buffering the effects of increased venous pressure by temporary occupation of an enlarged extravascular space. In the chronic condition this movement of fluid would lead to ascites and the presence of ANF in ascitic fluid 
